ReviewClinical medicine (London, England)2024
Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management.
Review in Clinical medicine (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease.Scientific reports · 2026Trial
- Gut-lung axis and microbiome alterations in mycobacterial infections: from pathogenesis to therapeutic potential.Gut microbes · 2026Review
- A review of tigecycline resistance in nontuberculous mycobacteria.Molecular biology reports · 2026Review
- Analysis of the differential clinical characteristics of tuberculosis and nontuberculous mycobacterial diseases among AIDS patients.Journal of clinical tuberculosis and other mycobacterial diseases · 2026Article
- Comparative evaluation of three commercial real-time PCR kits for direct detection ofMicrobiology spectrum · 2026Article
- Cytochrome P450-Mediated Metabolism of AntimycobacterialACS infectious diseases · 2026Article
- Pneumonia due to Mycobacterium shimoidei: a rare non-tuberculous mycobacterial infection in a young patient with anorexia nervosa.Infection · 2026Article
- Non-Tuberculous Mycobacteria at the Human-Animal-Environment Interface: Antimicrobial Resistance, Environmental Persistence and Cross-Species Exposure Risks.Antibiotics (Basel, Switzerland) · 2026Review
- Acidic pH Restricts Non-Tuberculous Mycobacteria Replication.Molecular microbiology · 2026Article
- Prevalence of nontuberculous mycobacteria isolates and pulmonary disease from respiratory tract samples in persons investigated for presumed tuberculosis from three West African countries, an analysis of three prospective cohort studies.BMC infectious diseases · 2026Article
- Enhanced In Vitro Stability of Bedaquiline with Ascorbic Acid and Pyruvate During Long-Term Incubation inAntibiotics (Basel, Switzerland) · 2026Article
- Molecular Techniques for MTBC and NTM Differentiation: Diagnostic Accuracy of STANDARD™ M10 MTB/NTM and Potential Applications.Diagnostics (Basel, Switzerland) · 2026Article
- Sarcopenia: an overlooked predictor of the progression risk in pulmonary nontuberculous mycobacterial infections?Journal of thoracic disease · 2026Article
- Molecular epidemiology of non-tuberculous mycobacteria in clinical samples from Jiangxi Province, 2021-2023.BMC microbiology · 2026Article
- Exploration of factors associated with turnaround time when evaluating non-tuberculous mycobacterium cultures.Frontiers in medicine · 2026Article
- Species Distribution and Antimicrobial Susceptibility Profiles of Non-Tuberculous Mycobacteria in Nanjing, Jiangsu Province, China: A Three-Year Retrospective Study.Infection and drug resistance · 2026Article
- Computational and Experimental Characterization ofBioinformatics and biology insights · 2026Article
- Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles inFrontiers in cellular and infection microbiology · 2026Article
- Early treatment interruption and nutritional status as predictors of mortality in Mycobacterium avium complex pulmonary disease.PloS one · 2026Article
- Serum HMGB1 and CA19-9 are independently associated with pulmonary cavity formation in patients with non-tuberculous mycobacterial pulmonary disease.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-tuberculous mycobacteria (NTM) are ubiquitous environmental organisms that can cause significant disease in both immunocompromised and immunocompetent individuals. The incidence of NTM pulmonary disease (NTM-PD) is rising globally. Diagnostic challenges persist and treatment efficacy is variable. This article provides an overview of NTM-PD for clinicians. We discuss how common it is, who is at risk, how it is diagnosed and the multidisciplinary approach to its clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.